Scarica l'app Stockscreener
259.84
5.71%
-15.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$275.64
Aprire:
$267.6
Volume 24 ore:
256.43K
Relative Volume:
0.87
Capitalizzazione di mercato:
$7.60B
Reddito:
$290.51M
Utile/perdita netta:
$89.16M
Rapporto P/E:
86.90
EPS:
2.99
Flusso di cassa netto:
$119.18M
1 W Prestazione:
-5.35%
1M Prestazione:
-7.92%
6M Prestazione:
+74.44%
1 anno Prestazione:
+45.00%
Intervallo 1D:
$259.00
$270.00
Intervallo di 1 settimana:
$259.00
$277.03
Portata 52W:
$122.80
$298.30
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
260.06 | 8.06B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.41 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.58 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.28 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.53 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.14 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
Krystal Biotech (KRYS) Is Up 5.6% After Stronger 2025 Profitability And EPS Growth Has The Bull Case Changed? - Sahm
Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 - Yahoo Finance
Krystal Biotech director Janney sells shares worth $10.1 million - Investing.com
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 700 Shares - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 37,895 Shares - MarketBeat
Daniel Janney Sells 7,741 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech Director Janney Daniel Sells Over $16 Million in Company Stock - TradingView
KRYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vanguard Group Inc. Cuts Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Assessing Krystal Biotech (KRYS) Valuation After Earnings Beat And Profitability Milestone - simplywall.st
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Krystal Biotech (NASDAQ:KRYS) Given New $284.00 Price Target at Guggenheim - MarketBeat
Guggenheim Raises Price Target for Krystal Biotech (KRYS) to $284 | KRYS Stock News - GuruFocus
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates - MSN
Risk On: Can Krystal Biotech Inc weather a recessionJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn
Insider Unloading: Dino A Rossi Sells Options, Realizes $5.04M - Benzinga
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Krystal Biotech’s KB707 RMAT Win Opens New Lung Cancer Chapter - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock - MarketBeat
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million - Investing.com
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million By Investing.com - Investing.com India
Director at Krystal Biotech (NASDAQ: KRYS) sells 18,950 shares - Stock Titan
Krystal Biotech, Inc. (KRYS) Stock Analysis: An Investor's Guide To A Promising 17% Upside - DirectorsTalk Interviews
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 - Yahoo Finance
Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating - Finviz
Aug EndMonth: What is the long term forecast for Giftify Inc stockInsider Selling & Expert Curated Trade Ideas - baoquankhu1.vn
Analysts Offer Predictions for Krystal Biotech Q2 Earnings - MarketBeat
Krystal Biotech, Inc. $KRYS Shares Sold by Aberdeen Group plc - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Trading Down 6.9%Here's Why - MarketBeat
HC Wainwright Forecasts Krystal Biotech Q1 Earnings - MarketBeat
Why Analysts See Krystal Biotech (KRYS) Story Shifting After New Data And Target Resets - Yahoo Finance
Krystal Biotech (KRYS): Citigroup Raises Price Target to $371 | - GuruFocus
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Cogent Biosciences (COGT) - The Globe and Mail
Reassessing Krystal Biotech (KRYS) After Strong 1-Year Rally And Vyjuvek Pipeline Focus - Yahoo Finance
Krystal Biotech stock reaches all-time high at 296.78 USD By Investing.com - Investing.com Australia
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark - Finviz
Buy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline - TipRanks
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2025 Earnings Call Transcript - Insider Monkey
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $323.00 - MarketBeat
KRYS: Chardan Capital Raises Price Target to $323.00, Maintains Buy Rating | KRYS Stock News - GuruFocus
Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts - Benzinga
Krystal Biotech targets global VYJUVEK expansion with Italy launch in H2 2026 while maintaining 90%–95% gross margin outlook - MSN
MSN Money - MSN
Readystate Asset Management LP Sells 77,631 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
CSL licenses Eli Lilly's clazakizumab to cut cardiac risk in end-stage kidney disease - AOL.com
Krystal Biotech (NASDAQ:KRYS) Hits New 1-Year High After Earnings Beat - MarketBeat
Decoding Krystal Biotech Inc (KRYS): A Strategic SWOT Insight - GuruFocus
KRYS Krystal Biotech Feb 17, 2026 Jefferies Maintains Buy - Meyka
Krystal Biotech Earnings Call Highlights Profitable Growth - TipRanks
Krystal Biotech (KRYS) Reports Strong Q4 Revenue and Expansion P - GuruFocus
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):